Mason Street Advisors LLC Boosts Position in Illumina, Inc. (ILMN)

Mason Street Advisors LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 1.2% in the 1st quarter, Holdings Channel reports. The firm owned 20,971 shares of the life sciences company’s stock after purchasing an additional 246 shares during the period. Mason Street Advisors LLC’s holdings in Illumina were worth $6,515,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Massmutual Trust Co. FSB ADV grew its stake in shares of Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 39 shares in the last quarter. First Manhattan Co. grew its stake in shares of Illumina by 18.8% during the first quarter. First Manhattan Co. now owns 3,464 shares of the life sciences company’s stock worth $1,076,000 after purchasing an additional 547 shares in the last quarter. Sapphire Star Partners LP acquired a new position in shares of Illumina during the fourth quarter worth $360,000. Machina Capital S.A.S. acquired a new position in shares of Illumina during the fourth quarter worth $1,099,000. Finally, Ardevora Asset Management LLP grew its stake in shares of Illumina by 14.2% during the first quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock worth $31,446,000 after purchasing an additional 12,600 shares in the last quarter. Hedge funds and other institutional investors own 90.80% of the company’s stock.

In other news, SVP Charles Dadswell sold 1,220 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $313.93, for a total value of $382,994.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Aimee L. Hoyt sold 298 shares of the company’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $304.63, for a total transaction of $90,779.74. Following the completion of the sale, the senior vice president now directly owns 2,297 shares of the company’s stock, valued at $699,735.11. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,329 shares of company stock valued at $15,648,675. 0.38% of the stock is owned by corporate insiders.

ILMN traded down $0.90 on Friday, reaching $308.95. The company had a trading volume of 7,197 shares, compared to its average volume of 1,035,657. Illumina, Inc. has a 1 year low of $261.61 and a 1 year high of $372.61. The stock has a market cap of $45.55 billion, a PE ratio of 54.65, a price-to-earnings-growth ratio of 2.13 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The firm had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. During the same period in the previous year, the company earned $1.45 earnings per share. Illumina’s quarterly revenue was up 8.2% compared to the same quarter last year. As a group, equities analysts expect that Illumina, Inc. will post 6.68 EPS for the current fiscal year.

A number of equities analysts recently commented on ILMN shares. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research note on Wednesday, February 13th. Deutsche Bank downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research note on Friday, January 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 target price for the company in a research note on Tuesday, April 2nd. Bank of America reiterated a “buy” rating and set a $355.00 target price on shares of Illumina in a research note on Wednesday, January 30th. Finally, Leerink Swann upgraded shares of Illumina to an “outperform” rating and lowered their target price for the stock from $380.00 to $365.00 in a research note on Wednesday, January 30th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $353.58.

TRADEMARK VIOLATION NOTICE: “Mason Street Advisors LLC Boosts Position in Illumina, Inc. (ILMN)” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2019/05/17/mason-street-advisors-llc-boosts-position-in-illumina-inc-ilmn.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: How does new data get added to a blockchain?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.